<DOC>
	<DOCNO>NCT01402401</DOCNO>
	<brief_summary>This study ass safety efficacy AUY922 , administer , combination trastuzumab adult patient HER2+ advance gastric cancer , receive trastuzumab plus chemotherapy first line .</brief_summary>
	<brief_title>Phase II AUY922 Second-line Gastric Cancer Combination With Trastuzumab HER2 Positive Patients</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patients eligible inclusion study meet follow criterion : 1 . Written inform consent obtain prior screen procedure 2 . Patients document cytological histological confirm gastric adenocarcinoma gastroesophageal junction adenocarcinoma proven HER2 positive . 3 . Patients progressive disease ( radiological confirmation require accord RECIST ) first line trastuzumab combination chemotherapy advance gastric cancer . 4 . Age ≥ 18 year age consent country residence able sign Informed Consent 5 . ECOG performance status 01 study entry 6 . HER2overexpressing positive gastric tumor IHC3+ IHC2+ positive situ hybridization 7 . Measurable disease accord RECIST ( Irradiated lesion consider measurable unless clearly progress since radiotherapy ) . 8 . Negative serum pregnancy test . The serum pregnancy test must obtain prior drug administration ( ≤ 72 hour prior dose ) premenopausal woman woman &lt; 2 year onset menopause . 9 . Patients must follow laboratory value : Hematologic Absolute Neutrophil Count ( ANC ) ≥1.5x109/L , Hemoglobin ( Hgb ) ≥ 9 g/dL , Platelets ( plt ) ≥100x109/L Biochemistry : Serum total bilirubin ≤ 1.5 x ULN Serum albumin &gt; 2.5 g/dl Serum creatinine ≤ 1.5 x ULN 24hour clearance ≥ 50 ml/min . AST/SGOT ALT/SGPT ≤ 2.5 x Upper Limit Normal ( ULN ) ≤ 5.0 x ULN liver metastasis present Patients eligible study must meet following criterion : 1 . Evidence spinal cord compression current evidence CNS metastasis . CT/MRI brain mandatory ( within 3 week study start ) case clinical suspicion evidence brain metastasis 2 . Patient &lt; 4 week since last chemotherapy treatment another systemic anticancer agent . Patients must recover ( CTC ≤ 1 ) acute toxicity previous therapy ( exception alopecia ) . 3 . Patients may receive prior radiotherapy management local disease provide disease progression document , toxicity resolve ( CTC ≤ 1 ) ( exception alopecia ) , last fraction radiotherapy complete least 4 week prior study . 4 . Prior treatment agent act via HER2/cerbB2 target 1st line trastuzumab , include ( limited ) lapatinib pertuzumab . 5 . Treatment therapeutic dos coumarintype anticoagulant . ( Maximum daily dose 2 mg , line patency permit ) 6 . Patients malignant ascites require invasive treatment 7 . Patients acute chronic renal disease ; active chronic liver disease require intervention . Other concurrent severe and/or uncontrolled medical condition could cause unacceptable safety risk compromise compliance protocol . 8 . Major surgery ≤ 2 week prior enrollment recover therapy 9 . Impaired cardiac function 10 . Concurrent malignancy invasive cancer diagnose within past 5 year , except adequately treat basal cell cancer skin situ cancer cervix 11 . Patients receive chronic high dose corticosteroid therapy ( Inhaled steroid short course oral steroid antiemesis appetite stimulant allow ) 12 . Patients unwilling unable comply protocol 13 . Patients know HIV positive . Testing required absence clinical sign symptom suggest HIV infection . 14 . Known hypersensitivity study drug excipients 15 . Participation another clinical study within 30 day first study treatment 16 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/mL ) . 17 . Fertile woman childbearing potential ( WOCBP ) use adequate contraception ( abstinence , oral contraceptive , intrauterine device barrier method contraception conjunction spermicidal jelly surgically sterile ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>HER2+ ,</keyword>
	<keyword>Gastric Cancer ,</keyword>
	<keyword>HSP90 ,</keyword>
	<keyword>2nd-line ,</keyword>
	<keyword>Trastuzumab</keyword>
</DOC>